The tail end of the year is often a weak period for biotech flotations, so perhaps the fact that the companies that went public in Q4 of 2023 managed to raise more than those in either Q1 or Q2 is a hopeful sign.
Key Takeaways
- Just three floating biotechs raised a total of $617m in the fourth quarter of last year
- However, two of the three have seen their share prices grow since
- And the IPO climate might improve in the coming year, with obesity
Still, the $617m raised over the past three months is a retrenchment from the $1.3bn seen in Q3 of 2023
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
